Amneal Pharmaceuticals upgraded to Overweight from Neutral at JPMorgan
JPMorgan upgraded Amneal Pharmaceuticals (AMRX) to Overweight from Neutral with a price target of $12, up from $9. The firm cites the Crexont ...
Amneal launches Mesalamine; receives U.S. FDA Lenalidomide approval
Amneal Pharmaceuticals (AMRX) announced the launch of mesalamine 800 mg delayed-release tablets, an aminosalicylate indicated for the treatment ...
Amneal Launches Mesalamine and Receives U.S. FDA Approval for Lenalidomide
Mesalamine 800 mg delayed-release tablets, referencing ASACOL HD ® - Lenalidomide capsules, referencing REVLIMID ® BRIDGEWATER, N.J., February 19, 2025--(BUSINESS WIRE)--Amnea ...
Medical News Today26 天
Differences and similarities between proctitis and ulcerative colitis
Proctitis affects the rectum, whereas ulcerative colitis can affect the colon, the rectum, or both parts of the intestine. Ulcerative colitis (UC) is a form of inflammatory bowel disease (IBD ...
Frontiers8 个月
Identification of drug targets for Sjögren’s syndrome: multi-omics Mendelian ...
Background: Targeted therapy for Sjögren’s syndrome (SS) has become an important focus for clinicians. Multi-omics-wide Mendelian randomization (MR) analyses have provided new ideas for identifying ...